Skip to main content
. 2022 Aug 23;12(1):7–18. doi: 10.1159/000526639

Fig. 3.

Fig. 3

Kaplan-Meier curves of OS for individual patient data extracted from combination systemic therapies for aHCC. Anti-PD-(L)1/VEGF Ab, anti-programmed death-1/programmed death-ligand-1 pathway plus vascular endothelial growth receptor monoclonal antibody; Ate-Cab, atezolizumab-cabozantinib; T300+D, tremelimumab-durvalumab.